From: Monitoring serum HER2 levels in breast cancer patients
N | sHer2 values | p values a | ||
---|---|---|---|---|
Patients (N) | 118 | 5.750 +/− 3.495 | ||
Race | Asian | 7 | 9.11 | 0.041 |
Caucasian | 81 | 5.23 | ||
African American | 30 | 6.36 | ||
Age at diagnosis(years) | mean ± sd | 54.10 +/−13.81 | 0.813 | |
≤45 | 32 | 5.38 | ||
>45 | 86 | 5.89 | ||
Tumor size (cm) | mean ± sd | 2.8- +/− 2.33 | .852 | |
T1 | <2 | 53 | 5.49 | |
T2 | 2-5 | 53 | 5.81 | |
T3 | >5 | 11 | 6.27 | |
N/A | 1 | |||
(+) axilla lymph node(s) | 0 | 63 | 5.47 | 1.000 |
≥1 | 55 | 6.07 | ||
Receptor subtype | tHer2+ | 23 | 8.18 | .032 |
tHer2-, ER/PR+ | 77 | 5.02 | ||
TNBC | 18 | 5.79 | ||
Clinical Outcome | Disease Present | 12 | 8.50 | 0.007 |
Disease Absent | 106 | 5.44 | ||
Length of Follow Up (Months) | Mean ± sd | 23.51 +/− 11.38 | ||
Median | 21.32 |